Cargando…

Unveiling the Synergistic Interaction Between Liposomal Amphotericin B and Colistin

Patients with multiple comorbidities are often administered simultaneously or sequentially antifungals and antibacterial agents, without full knowledge of the consequences of drug interactions. Considering the clinical relevance of liposomal amphotericin B (L-AMB), the association between L-AMB and...

Descripción completa

Detalles Bibliográficos
Autores principales: Teixeira-Santos, Rita, Ricardo, Elisabete, Branco, Ricardo J., Azevedo, Maria M., Rodrigues, Acácio G., Pina-Vaz, Cidália
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020089/
https://www.ncbi.nlm.nih.gov/pubmed/27679618
http://dx.doi.org/10.3389/fmicb.2016.01439
_version_ 1782453171528925184
author Teixeira-Santos, Rita
Ricardo, Elisabete
Branco, Ricardo J.
Azevedo, Maria M.
Rodrigues, Acácio G.
Pina-Vaz, Cidália
author_facet Teixeira-Santos, Rita
Ricardo, Elisabete
Branco, Ricardo J.
Azevedo, Maria M.
Rodrigues, Acácio G.
Pina-Vaz, Cidália
author_sort Teixeira-Santos, Rita
collection PubMed
description Patients with multiple comorbidities are often administered simultaneously or sequentially antifungals and antibacterial agents, without full knowledge of the consequences of drug interactions. Considering the clinical relevance of liposomal amphotericin B (L-AMB), the association between L-AMB and six antibacterial agents was evaluated against four clinical isolates and one type strain of Candida spp. and two clinical isolates and one type strain of Aspergillus fumigatus. In order to evaluate such combined effects, the minimal inhibitory concentration (MIC) of L-AMB was determined in the presence of 0.5-, 1-, 2-, and 4-fold peak plasma concentrations of each of the antibacterial drugs. Since the L-AMB/colistin (CST) association was the most synergic, viability assays were performed and the physiological status induced by this association was characterized. In addition, computational molecular dynamics studies were also performed in order to clarify the molecular interaction. The maximum synergistic effect with all antibacterial agents, except CST, was reached at fourfold the usual peak plasma concentrations, resulting in 2-to 8-fold L-AMB MIC reduction for Candida and 2-to 16-fold for Aspergillus. For CST, the greatest synergism was registered at peak plasma concentration (3 mg/L), with 4-to 8-fold L-AMB MIC reduction for Candida and 16-to 32-fold for Aspergillus. L-AMB at subinhibitory concentration (0.125 mg/L) combined with CST 3 mg/L resulted in: a decrease of fungal cell viability; an increase of cell membrane permeability; an increase of cellular metabolic activity soon after 1 h of exposure, which decreased until 24 h; and an increase of ROS production up to 24 h. From the molecular dynamics studies, AMB and CST molecules shown a propensity to form a stable molecular complex in solution, conferring a recognition and binding added value for membrane intercalation. Our results demonstrate that CST interacts synergistically with L-AMB, forming a stable complex, which promotes the fungicidal activity of L-AMB at low concentration.
format Online
Article
Text
id pubmed-5020089
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-50200892016-09-27 Unveiling the Synergistic Interaction Between Liposomal Amphotericin B and Colistin Teixeira-Santos, Rita Ricardo, Elisabete Branco, Ricardo J. Azevedo, Maria M. Rodrigues, Acácio G. Pina-Vaz, Cidália Front Microbiol Microbiology Patients with multiple comorbidities are often administered simultaneously or sequentially antifungals and antibacterial agents, without full knowledge of the consequences of drug interactions. Considering the clinical relevance of liposomal amphotericin B (L-AMB), the association between L-AMB and six antibacterial agents was evaluated against four clinical isolates and one type strain of Candida spp. and two clinical isolates and one type strain of Aspergillus fumigatus. In order to evaluate such combined effects, the minimal inhibitory concentration (MIC) of L-AMB was determined in the presence of 0.5-, 1-, 2-, and 4-fold peak plasma concentrations of each of the antibacterial drugs. Since the L-AMB/colistin (CST) association was the most synergic, viability assays were performed and the physiological status induced by this association was characterized. In addition, computational molecular dynamics studies were also performed in order to clarify the molecular interaction. The maximum synergistic effect with all antibacterial agents, except CST, was reached at fourfold the usual peak plasma concentrations, resulting in 2-to 8-fold L-AMB MIC reduction for Candida and 2-to 16-fold for Aspergillus. For CST, the greatest synergism was registered at peak plasma concentration (3 mg/L), with 4-to 8-fold L-AMB MIC reduction for Candida and 16-to 32-fold for Aspergillus. L-AMB at subinhibitory concentration (0.125 mg/L) combined with CST 3 mg/L resulted in: a decrease of fungal cell viability; an increase of cell membrane permeability; an increase of cellular metabolic activity soon after 1 h of exposure, which decreased until 24 h; and an increase of ROS production up to 24 h. From the molecular dynamics studies, AMB and CST molecules shown a propensity to form a stable molecular complex in solution, conferring a recognition and binding added value for membrane intercalation. Our results demonstrate that CST interacts synergistically with L-AMB, forming a stable complex, which promotes the fungicidal activity of L-AMB at low concentration. Frontiers Media S.A. 2016-09-13 /pmc/articles/PMC5020089/ /pubmed/27679618 http://dx.doi.org/10.3389/fmicb.2016.01439 Text en Copyright © 2016 Teixeira-Santos, Ricardo, Branco, Azevedo, Rodrigues and Pina-Vaz. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Teixeira-Santos, Rita
Ricardo, Elisabete
Branco, Ricardo J.
Azevedo, Maria M.
Rodrigues, Acácio G.
Pina-Vaz, Cidália
Unveiling the Synergistic Interaction Between Liposomal Amphotericin B and Colistin
title Unveiling the Synergistic Interaction Between Liposomal Amphotericin B and Colistin
title_full Unveiling the Synergistic Interaction Between Liposomal Amphotericin B and Colistin
title_fullStr Unveiling the Synergistic Interaction Between Liposomal Amphotericin B and Colistin
title_full_unstemmed Unveiling the Synergistic Interaction Between Liposomal Amphotericin B and Colistin
title_short Unveiling the Synergistic Interaction Between Liposomal Amphotericin B and Colistin
title_sort unveiling the synergistic interaction between liposomal amphotericin b and colistin
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020089/
https://www.ncbi.nlm.nih.gov/pubmed/27679618
http://dx.doi.org/10.3389/fmicb.2016.01439
work_keys_str_mv AT teixeirasantosrita unveilingthesynergisticinteractionbetweenliposomalamphotericinbandcolistin
AT ricardoelisabete unveilingthesynergisticinteractionbetweenliposomalamphotericinbandcolistin
AT brancoricardoj unveilingthesynergisticinteractionbetweenliposomalamphotericinbandcolistin
AT azevedomariam unveilingthesynergisticinteractionbetweenliposomalamphotericinbandcolistin
AT rodriguesacaciog unveilingthesynergisticinteractionbetweenliposomalamphotericinbandcolistin
AT pinavazcidalia unveilingthesynergisticinteractionbetweenliposomalamphotericinbandcolistin